Columnists

Columns

Rod Liddle

We’re deluding ourselves about gang violence

Hey, Londoners — been stabbed or shot yet this week? Just thought I’d check as the place seems to resemble, in its violence, downtown Mogadishu right now — and indeed is graced with many of the same kinds of people. That’s probably why you haven’t been stabbed or shot yet: the murdering has been committed

Brexit is fast becoming a Tory no-win

Theresa May’s Brexit dilemma is becoming more acute. Last week, she failed to garner the support of the Brexit inner cabinet for a so-called ‘new customs partnership’ with the European Union. Even so, May can’t and won’t drop the idea. She’s convinced that it is critical for solving the Irish border issue, and thus unlocking

Brexit has driven me mad, but I can’t let it go

Rosé wine is, I know, considered naff. Were you unaware of this you’d fast conclude as much from the incidence of lifestyle commentary informing us that rosé is newly smart. As with those columns advising that everyone is drinking sherry now, or that some prosecco is actually OK, or that men will be wearing skirts

Why should we give in to EU blackmail over the EU border?

In deference to public exhaustion, I’ve largely avoided Brexit in this slot. But a columnist’s output ought rightly to echo what she shouts at the television news. Big picture, the UK may have made an utter Horlicks of its putative withdrawal from the European Union because Britain should never have come to the EU with

The Spectator's Notes

The Spectator’s Notes | 10 May 2018

The point behind the argument about the Iran nuclear deal goes beyond precise nuclear facts. It is like the row over SALT II when Ronald Reagan succeeded Jimmy Carter as US President in 1981. SALT (the Strategic Arms Limitation Treaty) was not formally junked, but it did not operate because, after the Soviet invasion of

Any other business

A hot weekend for takeover deals and cycle racing

The bank holiday turned out to be a hot one, not least in the takeover arena. First, Shire Pharmaceutical accepted a £46 billion offer from Takeda of Japan — though the stock market did not seem wholly convinced that the deal will proceed. If it does, should we care? Shire is a FTSE100 company that